EWM
VIR icon

Endurance Wealth Management’s Vir Biotechnology VIR Stock Holding History

Endurance Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-150
Closed -$5K – 672
2020
Q4 		$5K Hold
150
– – ﹤0.01% 531
2020
Q3 		$5K Buy
+150
New +$6.46K ﹤0.01% 534

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.28B AUM 16.36% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Endurance Wealth Management's VIR Position: Q1 2021 in Review

Endurance Wealth Management sold out of Vir Biotechnology (VIR) in Q1 2021, closing a stake of 150 shares — an estimated $5K sold.

Endurance Wealth Management first reported a position in VIR in Q3 2020 and held it in 2 quarters. The position peaked at $5K in Q4 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

  • Endurance Wealth Management reported no remaining Vir Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Endurance Wealth Management sold 150 Vir Biotechnology shares in Q1 2021, an estimated $5K.
  • Endurance Wealth Management first reported a position in Vir Biotechnology in Q3 2020 and held it in 2 quarters.
  • Endurance Wealth Management's Vir Biotechnology position peaked at $5K in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Endurance Wealth Management's 13F filing for Q1 2021, filed 5 May 2021.